Diagnosoft develops cardiovascular clinical analytics and magnetic resonance imaging (MRI) analysis software that assists in the diagnosis, staging and therapeutic monitoring of cardiovascular disease. The company's products include FUSION, a clinical analytics system that aggregates patient-specific data from various relevant health information systems; HARP, a software for the analysis of tagged magnetic resonance images; SENC, a MR imaging technique that measures regional contraction and relaxation of the heart's myocardium; CORE that analyzes cine MR images and provides segmentation and identification of endocardium and epicardium, and measures ventricular volume, mass, ejection fraction, wall thickening, wall thickness, and other global and morphological measures; FLOW that measures the blood flow of major vessels from phase contrast MR images; and STAR that enables physicians to calculate T2 from cardiac magnetic resonance images using mathematical algorithm. Otherproducts include PULSE, a cardiac MRI quantification tool that generates patient-specific structured reports based on results obtained by Diagnosoft VIRTUE and other vendors quantification results; and Diagnosoft OMNEA, an enterprise connectivity platform that serves as the middleware backbone for various Diagnosoft products. The company is known for developing HARP, the first FDA 510k-cleared software for tagged MR images, which is a component of the companyâs complete end-to-end solution for the analysis and quantification of cardiac magnetic resonance images. The company also develops clinical analytics solutions for healthcare. The company's software compiles and analyzes data directly from EMRs and other sources, and gives healthcare providers a view of the patientâs status right at the point of care. Diagnosoftâs core MRI technologies were co-developed at Johnâs Hopkins University and commercialized following several patent grants i
